Our new report examines current and future prospects for the inflammatory bowel disease (IBD) drug market. The global market for IBD drugs exceeded $5bn in 2009, with strong growth from the previous year. We predict that the overall market for IBD drugs will expand from 2010 onwards. Main commercial drivers will be disease prevalence, improving diagnosis and wider access to treatments. Currently, IBD is under-diagnosed, especially in developing countries. As governments and other healthcare providers address chronic illnesses like IBD, this market will expand in many countries.

Inflammatory Bowel Disease: World Market 2010-2025 analyses commercial prospects for drugs used to treat IBD, including R&D pipeline developments. How much impact will monoclonal antibodies have on the future market? Which products are most likely to meet therapeutic needs in future years? Can newer therapies compete successfully with established treatments? How will the European IBD market share compare with the Asian market share in 2015, 2020 and 2025? Our report covers questions such as these, providing answers to benefit your work.

In particular, this report covers market prospects for the following agents:
• Aminosalicylates/5-ASA
• Corticosteroids
• Immunomodulators
• Antibiotics
• Monoclonal antibodies/biologics.

The IBD treatment market is complex. Un-met and under-met therapeutic needs provide an impetus to drug developers, with high technological and commercial potential in this sector, our new study reveals.

Comprehensive analysis of the global IBD drug market

Inflammatory Bowel Disease: World Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 65 tables and figures included, as well as four original interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.


Report Highlights
Companies Listed
Abbott Laboratories
Amalyte
ARCA
AstraZeneca
Biogen Idec
Cambridge Antibody Technology
Celltech Pharmaceuticals
Centocor Ortho Biotech
ChemoCentryx
China Medical
Cosmo Pharmaceuticals
Crohn's and Colitis Foundation of America
Crohn's and Colitis Foundation of Canada
Dr. Falk Pharma
Elan Corporation
Enzo Biochem
European Federation of Crohn's and Ulcerative Colitis Associations
European Medicines Agency (EMEA)
Evonik Industries
Ferring Pharmaceuticals
Food and Drug Administration (FDA)
Giaconda
Giuliani
GlaxoSmithKline
Interneuron
Isis Pharmaceuticals
Johnson & Johnson
King's College, London, UK
Kyorin Pharmaceutical Co.
Medarex
Merck and Co.
Miltenyi Biotec
Nycomed
Otsuka Pharmaceutical Group
PDL BioPharma
Pfizer
Probiotic Therapy Research Centre, Sydney, Australia
Procter & Gamble
Prometheus Laboratories
Protein Design Labs
Royalty Pharma
Salix Pharmaceuticals
sanofi-aventis
Schering-Plough
Shire Pharmaceuticals Group
Takeda Pharmaceutical Company
Tillots Pharma
UCB
University of Auckland, New Zealand
[Studien Infos ausblenden]

1. Executive Summary
1.1 Inflammatory Bowel Disease Market Review
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. What Is Inflammatory Bowel Disease?
2.1 Definition
2.2 Types of IBD
2.3 Signs, Symptoms and Associated Conditions
2.3.1 Bleeding Ulcers, Fistulae, Bowel Perforations and Other Events
2.3.2 Pyoderma Gangrenosum
2.3.3 Primary Sclerosing Cholangitis
2.4 Ulcerative Colitis
2.5 Crohn's Disease
2.6 Indeterminate Colitis: Distinguishing Crohn's Disease from Ulcerative Colitis
2.7 What Causes Inflammatory Bowel Disease?
2.7.1 Genetic Factors
2.7.2 Environmental Factors
2.8 How Common is Inflammatory Bowel Disease?
2.8.1 Geographical Variation in Rates of IBD
2.9 Socioeconomic Costs of IBD
2.9.1 The Individual Cost of IBD

3. Treating Inflammatory Bowel Disease
3.1 Treatment Goals
3.2 Drug Classes Used in IBD Treatment
3.2.1 Aminosalicylates
3.2.2 Corticosteroids
3.2.3 Immunomodulators
3.2.4 Monoclonal Antibodies
3.3 Surgery
3.3.1 Surgery for Ulcerative Colitis
3.3.2 Surgery for Crohn's Disease
3.4 Alternative Treatments
3.4.1 Faecal Bacteriotherapy and Pre/Probiotics
3.4.2 Helminthic Therapy
3.4.3 Complementary Medicine
3.5 Treatment Protocol
3.5.1 Recent Trial Data

4. The World Inflammatory Bowel Disease Market, 2010-2025
4.1 Non-Biologic Drugs
4.1.1 IBD-Specific Drugs (Intestinal Anti-inflammatories)
4.1.2 Drugs not Specific to IBD (Others)
4.2 Biologic Drugs
4.3 Total Market
4.4 Market Shares by Disease Type
4.5 Market Forecast: Inflammatory Bowel Disease Sales
4.6 Market Forecasts: Sales by Disease Type
4.7 Market Forecasts: Sales by Therapy Type

5. Leading Drugs for Inflammatory Bowel Disease, 2010-2025
5.1 Intestinal Anti-inflammatory Drugs
5.2 Asacol
5.2.1 Asacol: Background
5.2.2 Asacol: Sales Forecast and Analysis
5.3 Pentasa
5.3.1 Pentasa: Background
5.3.2 Pentasa: Sales Forecast and Analysis
5.4 Entocort
5.4.1 Entocort: Background
5.4.2 Entocort: Sales Forecast and Analysis
5.5 Lialda
5.5.1 Lialda: Background
5.5.2 Lialda: Sales Forecast and Analysis
5.6 Salofalk
5.6.1 Salofalk: Background
5.6.2 Salofalk: Sales Forecast and Analysis
5.7 Comparison of Intestinal Anti-inflammatory Sales Forecasts
5.8 Biologics
5.9 Remicade
5.9.1 Remicade: Background
5.9.2 Remicade: Sales Forecast and Analysis
5.10 Humira
5.10.1 Humira: Background
5.10.2 Humira: Sales Forecast and Analysis
5.11 Cimzia
5.11.1 Cimzia: Background
5.11.2 Cimzia: Sales Forecast and Analysis
5.12 Tysabri
5.12.1 Tysabri: Background
5.12.2 Tysabri: Sales Forecast and Analysis
5.13 Comparison of Biologic Sales Forecasts

6. The R&D Pipeline for Inflammatory Bowel Disease
6.1 Monoclonal Antibodies
6.1.1 HuZAF
6.1.2 Stelara
6.1.3 Vedolizumab
6.1.4 Simponi
6.2 Small Molecules
6.2.1 Tetomilast
6.2.2 Firategrast
6.3 Antibiotics
6.3.1 Rifaximin
6.3.2 Myoconda
6.4 Nicotine and Buproprion
6.5 Alicaforsen
6.6 Alequel
6.7 MAP Vaccine
6.8 Autologous Stem Cell Transplantation for Crohn's Disease
6.9 Technologies That Deliver Drugs to Affected Parts of the GI Tract

7. Leading Companies in the Inflammatory Bowel Disease Sector
7.1 The Largest Companies by Revenue in the Intestinal Anti-inflammatory Market
7.2 Procter & Gamble
7.3 Shire Pharmaceuticals Group
7.4 Prometheus Laboratories
7.5 Ferring Pharmaceuticals
7.6 Kyorin Pharmaceutical

8. Geographical Breakdown of the World IBD Market, 2010-2025
8.1 Intestinal Anti-inflammatory Market: Seven Major Economies
8.2 Intestinal Anti-inflammatory Market: BRICT Countries
8.3 The Global IBD Market: Sales Forecasts by Geographical Area
8.3.1 North America: Sales Forecast, 2010-2025
8.3.2 Europe: Sales Forecast, 2010-2025
8.3.3 Africa, Asia and Australasia: Sales Forecast, 2010-2025
8.3.4 Latin America: Sales Forecast, 2010-2025
8.4 Comparison of Regional Markets: Sales Forecasts, 2010-2025

9. Inflammatory Bowel Disease Market: Opportunities and Challenges Ahead
9.1 SWOT Analysis of the World IBD Market
9.2 Market Drivers
9.2.1 Increasing Disease Incidence
9.2.2 Better Diagnosis
9.2.3 Nature of the Disease
9.2.4 Delivery Systems
9.2.5 Biologics
9.3 Market Restraints
9.3.1 Lack of Understanding of Disease Aetiology
9.3.2 Compliance
9.3.3 Limits of Biologics
9.3.4 A Cure or Vaccine?

10. Interviews with Experts
10.1 Marco Greco
10.1.1 Public Awareness of IBD
10.1.2 The Differences Between European Countries
10.1.3 Drug Companies' Involvement in Awareness Campaigns
10.1.4 Unmet Medical Needs
10.2 Dr Alan Fraser
10.2.1 Autoimmunity vs. Infection Theories
10.2.2 Monoclonal Antibodies
10.2.3 Genotyping
10.2.4 Remaining Therapeutic Gaps
10.2.5 Future Treatments
10.3 Professor Thomas Borody
10.3.1 Mycobacterium Avium Paratuberculosis (MAP) Infection and IBD Aetiology
10.3.2 IBD and HIV/AIDS
10.3.3 Monoclonal Antibodies and Immunosuppressant Treatments
10.3.4 Potential Cure?
10.3.5 Remicade and MAP
10.3.6 Genotyping
10.3.7 Crohn's vs. Colitis
10.3.8 Future Therapies
10.3.9 Potential and Future of Myoconda
10.4 Professor John Hermon-Taylor
10.4.1 Significance of MAP in Crohn's
10.4.2 The Rising Incidence of IBD
10.4.3 Defining IBD
10.4.4 Timeframe of MAP Vaccine
10.4.5 Antibiotic Activity of Other Crohn's Treatments
10.4.6 Alternative Treatments
10.4.7 Ethics of Crohn's Drug Development
10.4.8 Impact of a Vaccine on the Market
10.4.9 On Claims that MAP is Not Implicated in CD

11. Conclusions of the Study
11.1 IBD Sales to 2025 – How High Will The Market Reach?
11.2 Non-Biologic Treatments
11.3 Biologic Treatments
11.4 Improvements Needed in IBD Treatment
11.5 Future IBD Treatments: R&D Efforts Promising
11.6 The IBD Sector: Looking to the Future Confidently
[Inhaltsverzeichnis ausblenden]

Table 2.1 World Incidence Rates for IBD, 2010
Table 2.2 Prevalence of IBD in Selected Countries, 2010
Table 2.3 Common Misdiagnoses for IBD
Table 3.1 Ancillary Drug Types Used in Inflammatory Bowel Disease, 2010
Table 3.2 Composition of Various 5-ASA Drugs
Table 4.1 Inflammatory Bowel Disease Market: World Sales and Market Shares by Drug Class, 2009
Table 4.2 Studies Comparing the Direct Medical Costs of Crohn’s Disease and Ulcerative Colitis
Table 4.3 World IBD Market: Sales by Disease Type, 2009
Table 4.4 World IBD Market: Sales Forecast, 2010-2025
Table 4.5 World IBD Market: Sales Forecast by Disease Type, 2010-2025
Table 4.6 World IBD Market: Sales Forecast by Therapy Type, 2010-2025
Table 5.1 Top-Five Intestinal Anti-Inflammatory Drugs: World Sales, 2009
Table 5.2 Asacol: World Sales Forecast, 2010-2025
Table 5.3 Pentasa: World Sales Forecast, 2010-2025
Table 5.4 Entocort: World Sales Forecast, 2010-2025
Table 5.5 Lialda: World Sales Forecast, 2010-2025
Table 5.6 Salofalk: World Sales Forecast, 2010-2025
Table 5.7 World Sales Forecasts for Leading Intestinal Anti-Inflammatories, 2010-2025
Table 5.8 Biologics for IBD: World Sales, 2009
Table 5.9 Remicade: World Sales Forecast, 2010-2025
Table 5.10 Contraindications for TNF-a Blockers
Table 5.11 Humira: World Sales Forecast, 2010-2025
Table 5.12 Cimzia: World Sales Forecast, 2010-2025
Table 5.13 Tysabri: World Sales Forecast, 2010-2025
Table 5.14 World Sales Forecasts for Biologics Indicated for IBD, 2010-2025
Table 6.1 Key Pipeline Products for Inflammatory Bowel Disease, 2010
Table 7.1 Intestinal Anti-Inflammatories (IAIs): Largest Companies by Revenue, 2009
Table 7.2 Procter & Gamble: Major IAI Products, 2009
Table 7.3 Shire: Major IAI Products, 2009
Table 7.4 Prometheus: Major IAI Products, 2009
Table 7.5 Prometheus: Diagnostic Tests, 2009
Table 7.6 Ferring: Major IAI Products, 2009
Table 7.7 Kyorin: Major IAI Products, 2009
Table 8.1 IBD Markets of Seven Major Economies: Sales and Market Shares, 2009
Table 8.2 IBD Sales and Market Shares for the Major Emerging Markets (BRICT), 2009
Table 8.3 North America: IBD Sales Forecast, 2010-2025
Table 8.4 Europe: IBD Sales Forecast, 2010-2025
Table 8.5 Africa, Asia and Australasia: IBD Sales Forecast, 2010-2025
Table 8.6 Latin America: IBD Sales Forecast, 2010-2025
Table 8.7 IBD Sales Forecasts by Geographical Region, 2010-2025
Table 9.1 SWOT Analysis of the Global IBD Market, 2010

Figure 2.1 Prevalence of IBD in Selected Countries, 2010
Figure 3.1 Treatment Protocols for Inflammatory Bowel Disease, 2010
Figure 4.1 World IBD Market: Sales Shares by Drug Class, 2009
Figure 4.2 World IBD Market: Sales Shares by Disease Type, 2009
Figure 4.3 World IBD Market: Sales Forecast, 2010-2025
Figure 4.4 World IBD Market: Sales Forecasts by Disease Type, 2010-2025
Figure 4.5 World IBD Market: Sales Forecasts by Therapy Type, 2010-2025
Figure 5.1 Top-Five Intestinal Anti-Inflammatories: World Market Shares, 2009
Figure 5.2 Asacol: World Sales Forecast, 2010-2025
Figure 5.3 Pentasa: World Sales Forecast, 2010-2025
Figure 5.4 Entocort: World Sales Forecast, 2010-2025
Figure 5.5 Lialda: World Sales Forecast, 2010-2025
Figure 5.6 Salofalk: World Sales Forecast, 2010-2025
Figure 5.7 World Sales Forecasts for Leading Intestinal Anti-inflammatory Drugs, 2010-2025
Figure 5.8 Biologics for IBD: World Sales, 2009
Figure 5.9 Remicade: World Sales Forecast, 2010-2025
Figure 5.10 Humira: World Sales Forecast, 2010-2025
Figure 5.11 Cimzia: World Sales Forecast, 2010-2025
Figure 5.12 Tysabri: World Sales Forecast, 2010-2025
Figure 5.13 World Sales Forecasts for Biologics Indicated for IBD, 2010-2025
Figure 7.1 Intestinal Anti-Inflammatories: Largest Companies by Sales, 2009
Figure 8.1 IBD Markets of Seven Major Economies: Sales, 2009
Figure 8.2 IBD Markets of Major Emerging Markets (BRICT): Sales, 2009
Figure 8.3 North America: IBD Sales Forecast, 2010-2025
Figure 8.4 Europe: IBD Sales Forecast, 2010-2025
Figure 8.5 Africa, Asia and Australasia: IBD Sales Forecast, 2010-2025
Figure 8.6 Latin America: IBD Sales Forecast, 2010-2025
Figure 8.7 IBD Sales Forecasts by Geographical Region, 2010-2025
[Tabellenverzeichnis ausblenden]